论文部分内容阅读
目的:通过检测血清高尔基体蛋白73(Golgi protein73,GP73)的含量,探讨GP73在原发性肝癌(PHC)中的临床诊断价值。方法:本文共收集149例血清,其中原发性肝癌57例,慢性肝炎32例,肝硬化38例,健康人22例。应用酶联免疫定量检测血清GP73含量。并对57例原发性肝癌的GP73含量与其肿瘤大小、结节数量和对29例原发性肝癌术前与术后的GP73含量进行比较。结果:原发性肝癌患者血清GP73含量显著高于慢性肝炎,肝硬化患者和正常对照组,比较有显著差异(,P均0.05)。结论:检测血清GP73含量可作为诊断PHC的—个血清标志物,与AFP联检可提高对PHC的诊断敏感性,具有良好的临床应用价值。
Objective: To investigate the clinical value of GP73 in the diagnosis of primary hepatocellular carcinoma (PHC) by detecting the content of serum Golgi protein 73 (GP73). Methods: A total of 149 cases of serum collected in this study, including 57 cases of primary liver cancer, 32 cases of chronic hepatitis, cirrhosis of the 38 cases, 22 cases of healthy people. Serum GP73 levels were detected by enzyme-linked immunosorbent assay. The GP73 content in 57 cases of primary hepatocellular carcinoma was compared with the tumor size, the number of nodules and the GP73 contents of 29 cases of primary liver cancer before and after operation. Results: The serum levels of GP73 in patients with primary liver cancer were significantly higher than those in patients with chronic hepatitis, cirrhosis and normal controls (all P <0.01). The serum levels of GP73 in patients with chronic hepatitis and cirrhosis were significantly higher than those in patients with chronic hepatitis The normal control group, there are significant differences (P all <0.01). The sensitivity of GP73 to diagnose PHC reached 68.42%. GP73 content and tumor size, number of nodules, preoperative and postoperative were no significant difference (P> 0.05). Conclusion: The detection of serum GP73 level can be used as a serum marker for the diagnosis of PHC. Combined with AFP, it can improve the diagnostic sensitivity to PHC and has a good clinical value.